![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MYL9 |
Gene summary for MYL9 |
![]() |
Gene information | Species | Human | Gene symbol | MYL9 | Gene ID | 10398 |
Gene name | myosin light chain 9 | |
Gene Alias | LC20 | |
Cytomap | 20q11.23 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | P24844 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10398 | MYL9 | GSM4909281 | Human | Breast | IDC | 4.24e-68 | 1.14e+00 | 0.21 |
10398 | MYL9 | GSM4909282 | Human | Breast | IDC | 1.77e-02 | 2.84e-01 | -0.0288 |
10398 | MYL9 | GSM4909287 | Human | Breast | IDC | 2.13e-11 | 5.23e-01 | 0.2057 |
10398 | MYL9 | GSM4909291 | Human | Breast | IDC | 6.73e-04 | 4.47e-01 | 0.1753 |
10398 | MYL9 | GSM4909294 | Human | Breast | IDC | 5.30e-07 | -2.11e-01 | 0.2022 |
10398 | MYL9 | GSM4909295 | Human | Breast | IDC | 7.51e-13 | 7.29e-01 | 0.0898 |
10398 | MYL9 | GSM4909296 | Human | Breast | IDC | 1.17e-02 | -1.53e-01 | 0.1524 |
10398 | MYL9 | GSM4909311 | Human | Breast | IDC | 1.62e-05 | -8.97e-02 | 0.1534 |
10398 | MYL9 | GSM4909315 | Human | Breast | IDC | 8.30e-08 | -2.25e-01 | 0.21 |
10398 | MYL9 | GSM4909319 | Human | Breast | IDC | 2.85e-07 | -1.49e-01 | 0.1563 |
10398 | MYL9 | GSM4909321 | Human | Breast | IDC | 1.81e-03 | -1.28e-01 | 0.1559 |
10398 | MYL9 | brca3 | Human | Breast | Precancer | 3.66e-09 | 3.96e-01 | -0.0263 |
10398 | MYL9 | brca10 | Human | Breast | Precancer | 7.92e-05 | 4.60e-01 | -0.0029 |
10398 | MYL9 | DCIS2 | Human | Breast | DCIS | 2.70e-11 | 4.85e-02 | 0.0085 |
10398 | MYL9 | AEH-subject1 | Human | Endometrium | AEH | 1.10e-34 | -8.34e-01 | -0.3059 |
10398 | MYL9 | AEH-subject2 | Human | Endometrium | AEH | 2.34e-31 | -7.85e-01 | -0.2525 |
10398 | MYL9 | AEH-subject3 | Human | Endometrium | AEH | 5.68e-27 | -7.60e-01 | -0.2576 |
10398 | MYL9 | AEH-subject4 | Human | Endometrium | AEH | 2.19e-27 | -7.98e-01 | -0.2657 |
10398 | MYL9 | AEH-subject5 | Human | Endometrium | AEH | 6.06e-39 | -8.26e-01 | -0.2953 |
10398 | MYL9 | EEC-subject1 | Human | Endometrium | EEC | 4.07e-39 | -8.78e-01 | -0.2682 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00075998 | Prostate | BPH | hemostasis | 53/3107 | 222/18723 | 3.21e-03 | 1.67e-02 | 53 |
GO:004206019 | Prostate | Tumor | wound healing | 127/3246 | 422/18723 | 5.32e-11 | 3.41e-09 | 127 |
GO:003410918 | Prostate | Tumor | homotypic cell-cell adhesion | 33/3246 | 90/18723 | 9.06e-06 | 1.32e-04 | 33 |
GO:009025713 | Prostate | Tumor | regulation of muscle system process | 66/3246 | 252/18723 | 2.54e-04 | 2.13e-03 | 66 |
GO:005087818 | Prostate | Tumor | regulation of body fluid levels | 91/3246 | 379/18723 | 5.37e-04 | 3.91e-03 | 91 |
GO:007052717 | Prostate | Tumor | platelet aggregation | 23/3246 | 67/18723 | 5.95e-04 | 4.27e-03 | 23 |
GO:000301214 | Prostate | Tumor | muscle system process | 105/3246 | 452/18723 | 7.44e-04 | 5.14e-03 | 105 |
GO:000759614 | Prostate | Tumor | blood coagulation | 53/3246 | 217/18723 | 4.89e-03 | 2.39e-02 | 53 |
GO:005081714 | Prostate | Tumor | coagulation | 54/3246 | 222/18723 | 4.95e-03 | 2.42e-02 | 54 |
GO:000759914 | Prostate | Tumor | hemostasis | 53/3246 | 222/18723 | 7.87e-03 | 3.50e-02 | 53 |
GO:004206028 | Skin | AK | wound healing | 91/1910 | 422/18723 | 2.93e-12 | 6.67e-10 | 91 |
GO:003410926 | Skin | AK | homotypic cell-cell adhesion | 26/1910 | 90/18723 | 6.25e-07 | 2.19e-05 | 26 |
GO:005087820 | Skin | AK | regulation of body fluid levels | 58/1910 | 379/18723 | 1.11e-03 | 8.61e-03 | 58 |
GO:000759910 | Skin | AK | hemostasis | 37/1910 | 222/18723 | 1.89e-03 | 1.29e-02 | 37 |
GO:000759610 | Skin | AK | blood coagulation | 36/1910 | 217/18723 | 2.34e-03 | 1.54e-02 | 36 |
GO:007052720 | Skin | AK | platelet aggregation | 15/1910 | 67/18723 | 2.64e-03 | 1.69e-02 | 15 |
GO:005081710 | Skin | AK | coagulation | 36/1910 | 222/18723 | 3.46e-03 | 2.10e-02 | 36 |
GO:00030129 | Skin | AK | muscle system process | 64/1910 | 452/18723 | 4.32e-03 | 2.52e-02 | 64 |
GO:009025714 | Skin | AK | regulation of muscle system process | 38/1910 | 252/18723 | 9.21e-03 | 4.52e-02 | 38 |
GO:0042060111 | Skin | SCCIS | wound healing | 63/919 | 422/18723 | 2.26e-15 | 6.00e-12 | 63 |
Page: 1 2 3 4 5 6 7 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513118 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
hsa0453018 | Breast | Precancer | Tight junction | 31/684 | 169/8465 | 1.13e-05 | 1.26e-04 | 9.64e-05 | 31 |
hsa0467018 | Breast | Precancer | Leukocyte transendothelial migration | 20/684 | 114/8465 | 7.26e-04 | 5.33e-03 | 4.09e-03 | 20 |
hsa0452018 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
hsa0513119 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
hsa0453019 | Breast | Precancer | Tight junction | 31/684 | 169/8465 | 1.13e-05 | 1.26e-04 | 9.64e-05 | 31 |
hsa0467019 | Breast | Precancer | Leukocyte transendothelial migration | 20/684 | 114/8465 | 7.26e-04 | 5.33e-03 | 4.09e-03 | 20 |
hsa0452019 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
hsa0513224 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
hsa0453024 | Breast | IDC | Tight junction | 38/867 | 169/8465 | 2.07e-06 | 3.20e-05 | 2.39e-05 | 38 |
hsa0513124 | Breast | IDC | Shigellosis | 47/867 | 247/8465 | 1.78e-05 | 2.00e-04 | 1.49e-04 | 47 |
hsa0467024 | Breast | IDC | Leukocyte transendothelial migration | 21/867 | 114/8465 | 5.41e-03 | 3.13e-02 | 2.34e-02 | 21 |
hsa0481014 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
hsa045109 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
hsa0513234 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
hsa0453034 | Breast | IDC | Tight junction | 38/867 | 169/8465 | 2.07e-06 | 3.20e-05 | 2.39e-05 | 38 |
hsa0513134 | Breast | IDC | Shigellosis | 47/867 | 247/8465 | 1.78e-05 | 2.00e-04 | 1.49e-04 | 47 |
hsa0467034 | Breast | IDC | Leukocyte transendothelial migration | 21/867 | 114/8465 | 5.41e-03 | 3.13e-02 | 2.34e-02 | 21 |
hsa0481015 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
hsa0451013 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYL9 | SNV | Missense_Mutation | c.228N>C | p.Glu76Asp | p.E76D | P24844 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-E9-A22A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
MYL9 | SNV | Missense_Mutation | rs768626963 | c.179C>T | p.Ser60Leu | p.S60L | P24844 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-JX-A3PZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
MYL9 | SNV | Missense_Mutation | novel | c.409N>A | p.Glu137Lys | p.E137K | P24844 | protein_coding | deleterious(0) | possibly_damaging(0.771) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MYL9 | SNV | Missense_Mutation | novel | c.17C>T | p.Ala6Val | p.A6V | P24844 | protein_coding | deleterious(0.03) | benign(0.04) | TCGA-AA-A02E-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
MYL9 | SNV | Missense_Mutation | c.20N>G | p.Lys7Arg | p.K7R | P24844 | protein_coding | tolerated(0.1) | benign(0.229) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MYL9 | SNV | Missense_Mutation | c.361N>A | p.Asp121Asn | p.D121N | P24844 | protein_coding | tolerated(0.09) | benign(0.111) | TCGA-AG-4001-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MYL9 | SNV | Missense_Mutation | c.40N>T | p.Arg14Trp | p.R14W | P24844 | protein_coding | deleterious(0) | possibly_damaging(0.609) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR | |
MYL9 | SNV | Missense_Mutation | c.351N>A | p.Phe117Leu | p.F117L | P24844 | protein_coding | tolerated(0.66) | benign(0) | TCGA-AH-6643-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | PD | |
MYL9 | SNV | Missense_Mutation | rs766224371 | c.233N>T | p.Pro78Leu | p.P78L | P24844 | protein_coding | deleterious(0.03) | benign(0.051) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
MYL9 | SNV | Missense_Mutation | rs768877867 | c.49N>T | p.Arg17Trp | p.R17W | P24844 | protein_coding | tolerated(0.07) | possibly_damaging(0.683) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |